Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer

Frontiers in Medicine

Markus Tolnay¹  Ivana Bratić Hench¹  Jürgen Hench¹ 

[1]Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland

关键词: liquid biopsy;    cell-free DNA;    ctDNA;    circulating tumor cell;    cancer;    screening;   

DOI  :  10.3389/fmed.2018.00009

来源: DOAJ

【 摘 要 】

Examination of tumor molecular characteristics by liquid biopsy is likely to greatly influence personalized cancer patient management. Analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and tumor-derived exosomes, all collectively referred to as “liquid biopsies,” are not only a modality to monitor treatment efficacy, disease progression, and emerging therapy resistance mechanisms, but they also assess tumor heterogeneity and evolution in real time. We review the literature concerning the examination of ctDNA and CTC in a diagnostic setting, evaluating their prognostic, predictive, and monitoring capabilities. We discuss the advantages and limitations of various leading ctDNA/CTC analysis technologies. Finally, guided by the results of clinical trials, we discuss the readiness of cell-free DNA and CTC as routine biomarkers in the context of various common types of neoplastic disease. At this moment, one cannot conclude whether or not liquid biopsy will become a mainstay in oncology practice.

【 授权许可】

Unknown